Analysts’ Weekly Ratings Changes for AgomAb Therapeutics (AGMB)

Several brokerages have updated their recommendations and price targets on shares of AgomAb Therapeutics (NASDAQ: AGMB) in the last few weeks:

• 3/3/2026 – AgomAb Therapeutics is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $32.00 price target on the stock.
• 3/3/2026 – AgomAb Therapeutics is now covered by Leerink Partners. They set an “outperform” rating and a $36.00 price target on the stock.
• 3/3/2026 – AgomAb Therapeutics is now covered by Morgan Stanley. They set an “overweight” rating and a $28.00 price target on the stock.
• 2/17/2026 – AgomAb Therapeutics was upgraded by Wall Street Zen to “hold”.

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.